PROK
ProKidney Corp.Healthcare · $494M market cap
Verdict
We can't put a fair value on PROK right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow PROK
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 28, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about PROK
Are insiders buying PROK?
Since Oct 28, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar).
How can I check PROK's value myself?
Use the free Sticker Price calculator, already filled with PROK's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About ProKidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 30, 2026. How the Payback Price works